Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07204782

Cardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize

Elevated Cardiovascular Risk Scores With Diabetes Mellitus Type 2 and Their Association With Non-Invasive Visceral Adiposity Indices

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
238 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

calculate cardiovascular risk scores in type 2 DM patients, then estimate its association with new visceral adipose tissue indices

Detailed description

Cardiovascular disease (CVD) constitutes a significant health challenge for individuals with type 2 diabetes mellitus (T2DM), affecting approximately 32% of this population and contributing significantly to global mortality.Visceral adipose tissue (VAT) accumulation has been recognized as a major contributor to adverse cardiac remodelling. Unlike subcutaneous adipose tissue (SAT), VAT is metabolically active, promoting a pro-inflammatory, lipotoxic, and insulin-resistant environment that accelerates myocardial fibrosis, hypertrophy, and diastolic dysfunction. Despite its clinical significance, VAT is challenging to measure in routine practice. Advanced imaging modalities such as magnetic resonance imaging provide direct VAT assessment but it's costly, time-consuming, and impractical for large-scale screening. In contrast, traditional anthropometric measures like body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) do not distinguish VAT from SAT and fail to capture the true cardiometabolic burden of visceral fat .To address these limitations, researchers have focused on developing non-invasive visceral obesity indices that combine anthropometric and laboratory-based parameters. These indices are particularly relevant for T2DM patients, as insulin resistance often occurs when fat accumulates in intra-abdominal depots and is associated with a constellation of CVD risk factors, in what is known as the metabolic syndrome.

Conditions

Timeline

Start date
2025-12-01
Primary completion
2027-04-01
Completion
2027-07-01
First posted
2025-10-02
Last updated
2025-10-02

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07204782. Inclusion in this directory is not an endorsement.